On this page
hydrocortisone and acetic acid
hydrocortisone and acetic acid otic · Solution
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Acetic Acid | 20 mg/mL | 197305 | View |
| Acetic Acid | 20.75 mg/mL | 197305 | View |
| Acetic Acid | 20.8 mg/mL | 197305 | View |
| Hydrocortisone | 10 mg/mL | 604449 | View |
| Hydrocortisone | 10.375 mg/mL | 604449 | View |
| Hydrocortisone | 10.4 mg/mL | 604449 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 012770-001 | VOSOL HC | SOLUTION/DROPS | ACETIC ACID, GLACIAL; HYDROCORTISONE | Prescription | AT | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 33 | Labeling | Approved | December 3, 2024 | Standard |
| Supplement | 25 | Manufacturing (CMC) | Approved | October 16, 1997 | Standard |
| Supplement | 24 | Labeling | Approved | July 29, 1997 | Standard |
| Supplement | 22 | Manufacturing (CMC) | Approved | December 21, 1995 | Standard |
| Supplement | 21 | Labeling | Approved | August 1, 1990 | — |
| Supplement | 20 | Manufacturing (CMC) | Approved | August 1, 1990 | Standard |
| Supplement | 19 | Manufacturing (CMC) | Approved | September 15, 1988 | Standard |
| Supplement | 18 | Manufacturing (CMC) | Approved | September 15, 1988 | Standard |
| Supplement | 16 | Labeling | Approved | June 29, 1988 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | August 26, 1986 | Standard |
| Supplement | 14 | Manufacturing (CMC) | Approved | June 24, 1985 | Standard |
| Supplement | 10 | Labeling | Approved | August 14, 1984 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | April 5, 1984 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | February 4, 1983 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | December 4, 1978 | Standard |
| Supplement | 9 | Labeling | Approved | July 25, 1978 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | April 7, 1976 | Standard |
| Supplement | 5 | Manufacturing (CMC) | Approved | June 2, 1975 | Standard |
| Supplement | 4 | Supplement | Approved | July 16, 1974 | Standard |
| Original application | 1 | Type 4 - New Combination | Approved | June 23, 1961 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250707). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: Carefully remove all cerumen and debris to allow Hydrocortisone and Acetic Acid to contact infected surfaces directly. To promote continuous contact, insert a wick of cotton saturated with Hydrocortisone and Acetic Acid into the ear canal; the wick may also be saturated after insertion. Instruct the patient to keep the wick in for at least 24 hours and to keep it moist by adding 3 to 5 drops of Hydrocortisone and Acetic Acid every 4 to 6 hours. The wick may be removed after 24 hours but the patient should continue to instill 5 drops of Hydrocortisone and Acetic Acid 3 or 4 times daily thereafter, for as long as indicated. In pediatric patients, 3 to 4 drops may be sufficient due to the smaller capacity of the ear canal.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hypersensitivity to hydrocortisone and acetic acid otic solution or any of the ingredients; herpes simplex, vaccinia and varicella. Perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.
Warnings
openFDA Drug LabelingWARNINGS: Discontinue promptly if sensitization or irritation occurs.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: Stinging or burning may be noted occasionally; local irritation has occurred very rarely. To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION Hydrocortisone and Acetic Acid Otic Solution, USP contains Hydrocortisone (1%) and acetic acid, glacial (2%) in a propylene glycol vehicle containing benzethonium chloride (0.02%), citric acid (0.2%), propylene glycol diacetate (3%) and sodium acetate (0.015%). Acetic acid has a molecular formula of CH 3 COOH with molecular weight of 60.05. The structural formula is: Hydrocortisone is a Synthetic Steroid used as an anti-inflammatory and antipruritic agent. Its chemical name is Pregn-4-ene-3,20-dione, 11, 17, 21-trihydroxy-, (11β)-. Hydrocortisone has a molecular formula of C 21 H 30 O 5 with molecular weight 362.46. The structural formula is: Hydrocortisone and acetic acid is available as a non-aqueous otic solution buffered at pH (2.0 to 4.0) for use in the external ear canal. Chemical Structure Chemical Structure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone 1% and acetic acid 2% otic solution is available in 10 mL plastic, controlled dropper tip bottle. 10 mL bottle NDC 51672-3007-1 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing. Keep container tightly closed.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class III | November 15, 2023 | Taro Pharmaceuticals Inc. | Failed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0713-0849-09 | 0713-0849 | Cosette Pharmaceuticals, Inc. | 1 BOTTLE in 1 CARTON (0713-0849-09) / 10 mL in 1 BOTTLE | February 1, 2024 |
| 71656-064-10 | 71656-064 | Saptalis Pharmaceuticals, LLC | 1 BOTTLE, DROPPER in 1 CARTON (71656-064-10) / 10 mL in 1 BOTTLE, DROPPER | February 23, 2024 |
| 51672-3007-1 | 51672-3007 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE in 1 CARTON (51672-3007-1) / 10 mL in 1 BOTTLE | April 28, 2005 |
| 0713-0849 | 0713-0849 | Cosette Pharmaceuticals, Inc. | — | February 1, 2024 |
| 71656-064 | 71656-064 | Saptalis Pharmaceuticals, LLC | — | February 23, 2024 |
| 51672-3007 | 51672-3007 | Sun Pharmaceutical Industries, Inc. | — | April 28, 2005 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.